Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 14/20 | 0.42 |
| ▸ | EDNRA | P25101 | 14/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335452 | 0.83 | L3MBTL1 (0.48) | L3MBTL1EDNRBEDNRALMNASMN1; SMN2 | |
| SCHEMBL9407404 | 0.76 | EDNRB (0.40) | L3MBTL1EDNRBEDNRALMNATDP1 | |
| SCHEMBL9412038 | 0.76 | EDNRB (0.43) | L3MBTL1EDNRBEDNRALMNASMN1; SMN2 | |
| SCHEMBL12757466 | 0.75 | LMNA (0.47) | L3MBTL1EDNRBEDNRALMNASMN1; SMN2 | |
| SCHEMBL14325441 | 0.74 | EDNRB (0.52) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL7825117 | 0.74 | EDNRB (0.52) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL14298965 | 0.74 | EDNRB (0.46) | EDNRBEDNRALMNASMN1; SMN2TDP1 | |
| SCHEMBL14298973 | 0.74 | EDNRB (0.46) | EDNRBEDNRALMNASMN1; SMN2TDP1 | |
| SCHEMBL439716 | 0.74 | LMNA (0.59) | L3MBTL1LMNASMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL7808396 | 0.73 | EDNRB (0.45) | EDNRBEDNRALMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | disclosed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | LY96, AIMP1, NLRP1 | L3MBTL1 3319/4885EDNRB 4586/4885EDNRA 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.